[Off-label use of acetazolamide in a patient with familial hemiplegic migraine and concomitant psychotic episodes].

Abstract

A 42-year-old patient with cognitive deficits due to childhood meningitis suffered from recurrent episodes of familial hemiplegic migraine. Additionally, he developed concomitant psychotic episodes requiring subsequent in-patient psychiatric treatment. Following combined neurological and psychiatric treatment he always recovered from the episodes within a few weeks time. Prophylactic treatment of migraine using topiramate and acetazolamide (off-label) prevented attacks for several months. When off-label compensation was refused and, as a consequence, the drug discontinued, hemiplegia relapsed within a few days. Hence, acetazolamide was prescribed again and the family paid for the medication. Since that time, the patient did not show severe attacks for at least 8 months apart from a transient attack induced by acute flu-like illness.

• Authors: Horst J Koch, André Sykora, Patrick Hausn
• Journal: Psychiatrische Praxis (Psychiatr Prax) Vol. 37 Issue 3 Pg. 148-51 (Apr 2010) ISSN: 1439-0876 [Electronic] Germany
• Vernacular Title: Off-label-Behandlung eines Patienten mit rezidivierender familiärer hemiplegischer Migräne und begleitenden vorübergehenden psychotischen Episoden.
• PMID: 20148382 (Publication Type: Case Reports, Journal Article)
• Copyright: Copyright Georg Thieme Verlag KG Stuttgart . New York.

Chemical References

• Anticonvulsants
• Carbonic Anhydrase Inhibitors
• Topiramate
• Fructose
• Acetazolamide

Topics

• Acetazolamide (economics, therapeutic use)
• Adult
• Anticonvulsants (economics, therapeutic use)
• Carbonic Anhydrase Inhibitors (economics, therapeutic use)
• Comorbidity
• Drug Costs (statistics & numerical data)
• Drug Therapy, Combination
• Financing, Personal (economics)
• Fructose (analogs & derivatives, therapeutic use)
• Germany
• Humans
• Insurance, Pharmaceutical Services (economics)
• Intellectual Disability (drug therapy, psychology)
• Male
• Migraine with Aura (drug therapy, psychology)
• National Health Programs (economics)
• Off-Label Use (economics)
• Psychotic Disorders (drug therapy, genetics, psychology)
• Topiramate
• Treatment Outcome